[1]俞佳雯,周 薏,林天龙(加拿大),等.乙肝肝纤维化中西医研究进展[J].陕西中医,2025,46(2):273-276,280.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]
　YU Jiawen,ZHOU Yi,LIN Tianlong,et al.Progress of traditional Chinese and Western medicine research on chronic hepatitis B hepatic fibrosis[J].,2025,46(2):273-276,280.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]
点击复制

乙肝肝纤维化中西医研究进展
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年2期
页码:
273-276,280
栏目:
综 述
出版日期:
2025-02-05

文章信息/Info

Title:
Progress of traditional Chinese and Western medicine research on chronic hepatitis B hepatic fibrosis
作者:
俞佳雯1; 2; 周 薏2; 林天龙3(加拿大); 阙任烨1
(1.上海中医药大学附属上海中西医结合医院,上海 200082; 2.上海中医药大学附属上海中医医院,上海 200071; 3.上海交通大学附属仁济医院,上海 200001)
Author(s):
YU Jiawen1; 2; ZHOU Yi2; LIN Tianlong3; QUE Renye1
(1.Shanghai Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200082,China; 2.Shanghai University of Traditional Chinese Medicine Affiliated Hospital of Traditional Chinese Medicine,Shanghai 200071,China; 3.Renji Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200001,China)
关键词:
肝纤维化;  慢性乙型肝炎;  辨证论治;  抗病毒;  中药联合;  进展研究
Keywords:
Hepatic fibrosis;  Chronic hepatitis B;  Syndrome differentiation and treatment;  Antiviral;  Chinese medicine combination;  Progress research
分类号:
R 657.31
DOI:
DOI:10.3969/j.issn.1000-7369.2025.02.027
文献标志码:
A
摘要:
肝纤维化(HF)是指各种病因导致的慢性肝脏疾病发展过程中,肝细胞反复受损后过度修复的一种病理改变,以细胞外基质弥漫性过度沉积及异常分布为特征。肝纤维化早期无显著的临床症状,易被忽略,若未得到有效干预,最终可导致肝硬化甚至肝癌的发生,严重危害人们的生命安全。除针对病因治疗以外,使用药物及时有效地逆转肝纤维化,是防治各种慢性肝病的关键策略。本文针对慢乙肝肝纤维化的西医流行病学、发病机制、检测手段、药物治疗以及中医病因病机、辨证施治的研究进展作一综述,以期为慢乙肝肝纤维化的中西医结合防治提供一定的参考价值。
Abstract:
Hepatic fibrosis(HF)is a pathological change caused by excessive repair of liver cells after repeated damage in the development of chronic liver diseases caused by various causes.It is characterized by widespread over-accumulation and irregular dispersion of extracellular matrix.In the early stage of HF,it is easy to be ignored because there is no significant clinical symptoms.If there is no effective intervention,it can eventually lead to cirrhosis and even liver cancer,seriously endangering people's life safety.In addition to the etiological treatment,the use of drugs to reverse HF in a timely and effective manner is a key strategy for the prevention and treatment of various chronic liver diseases.This article reviews the progress of Western medicine epidemiology,pathogenesis,detection methods,drug treatment,Chinese medicine etiology,machanism and dialectical argumentation of chronic hepatitis B hepatic fibrosis,in order to provide some reference value for the prevention and treatment of chronic hepatitis B hepatic fibrosis.

参考文献/References:

[1] 田艳茹.miR-133b与慢性乙型肝炎肝纤维化相关性研究[J].陕西医学杂志,2023,52(4):448-451.
[2] 李堃,葛飞,孙茂秋,等.健肝散体外对拉米夫定耐药株病毒表达抑制及增敏作用的研究[J].陕西中医,2023,44(9):1188-1192.
[3] LIU J,YU Y,ZHAO H,et al.Latest insights into the epidemiology,characteristics,and therapeutic strategies of chronic hepatitis B patients in indeterminate phase[J].Eur J Med Res,2024,29(1):343.
[4] 国家卫生健康委员会.中国卫生健康统计年鉴(2021)[M].北京:中国协和医科大学出版社,2021:47.
[5] SONGTANIN B,CHAISRIMANEEPAN N,MENDOZA R,et al.Burden,outcome and comorbidities of extrahepatic manifestations in hepatitis B virus infections[J].Viruses,2024,16(4):25-30.
[6] ZHANG M,SERNA-SALAS S,DAMBA T,et al.Hepatic stellate cell senescence in liver fibrosis:Characteristics,mechanisms and perspectives[J].Mech Ageing Dev,2021,199:111572.
[7] CHEN Z,JAIN A,LIU H,et al.Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis[J].J Pharmacol Exp Ther,2019,370(3):695-702.
[8] 郝少东,刘彩萍,李月廷,等.肝星状细胞活化相关信号通路在肝纤维化中的研究进展[J].胃肠病学和肝病学杂志,2022,31(2):131-135.
[9] LAI M,AFDHAL N H.Liver fibrosis determination[J].Gastroenterol Clin N,2019,48(2):281-289.
[10] 姜帆,李春香,李忠原.超声双模态影像技术联合动态增强磁共振检查对大鼠早期肝纤维化的评估价值实验研究[J].陕西医学杂志,2023,52(3):273-277.
[11] 程宁,李吉彦,李梅,等.乙肝相关肝纤维化的中西医治疗进展与思考[J].中国中医药现代远程教育,2023,21(24):197-199.
[12] 童庆东.恩替卡韦配合长效干扰素治疗乙肝的临床效果及对HBV-DNA和HBeAg转阴率的影响[J].中外医疗,2023,42(27):101-104.
[13] 吴晓宁,贾继东.坚持长期抗病毒治疗阻断和逆转肝纤维化[J].肝博士,2022,18(2):17-18.
[14] 李力,郭丽颖,贾建伟,等.益气活血方联合恩替卡韦治疗慢性乙型肝炎肝纤维化临床研究[J].中西医结合肝病杂志,2019,29(3):217-220.
[15] 翟芬芬,崔翔,冯楝,等.软肝方联合恩替卡韦治疗正虚血瘀型慢性乙型肝炎肝纤维化的临床研究[J].中西医结合肝病杂志,2021,31(11):987-989.
[16] 王峰.化瘀软坚汤联合恩替卡韦分散片对慢性乙型肝炎肝纤维化患者肝功能、肝纤维化等指标的影响[J].贵州医药,2020,44(5):718-719.
[17] 宋爱军.扶正固本散治疗慢性乙型肝炎肝纤维化患者的疗效观察[J].中西医结合肝病杂志,2021,31(7):619-621.
[18] 崔林阁,杨晓波,刘畅,等.健肝化纤胶囊联合恩替卡韦治疗脾虚血瘀型慢性乙型肝炎肝纤维化疗效观察[J].湖南中医药大学学报,2020,40(12):1153-1156.
[19] 余松,何杰,张颖.四逆散合四君子汤加味方联合保肝抗病毒药物治疗慢性乙型肝炎肝纤维化肝郁脾虚证42例临床研究[J].江苏中医药,2022,54(11):36-39.
[20] 王欢,张晓强.化纤柔肝饮辅助西药治疗乙型肝炎肝纤维化的效果观察及对血清IL-6、TNF-α及TGF-β1水平的影响[J].中国中医药科技,2022,29(4):579-581.
[21] 刘莉,杨静,李宗云,等.肝爽颗粒对慢性乙型肝炎肝纤维化(S1和S2期)肝郁脾虚兼血瘀证的早期防治疗效[J].中国实验方剂学杂志,2022,28(11):132-138.
[22] 蒋淑莲,谭善忠,文剑.柴芍六君汤治疗慢性乙型肝炎肝纤维化疗效及对患者血清Treg/Th17的影响[J].陕西中医,2021,42(9):1229-1232.
[23] 范灵芝,郭峰,赵年欣.和血柔肝方治疗慢性乙型肝炎肝纤维化肝郁脾虚证的临床研究[J].云南中医中药杂志,2021,42(1):54-57.
[24] 杜宜衡,刘欣灵,钟嘉图,等.小芩连汤联合恩替卡韦对慢性乙型肝炎肝纤维化患者肝功能、肝脏硬度值的影响[J].湖北中医药大学学报,2022,24(6):28-31.
[25] 谢爱泽,毛德文,石清兰,等.黄连温胆汤治疗慢性乙型肝炎肝纤维化肝胆湿热证的效果观察[J].临床肝胆病杂志,2020,36(7):1502-1507.
[26] 宋启琴,孔红言,何济南,等.愈肝龙胶囊联合恩替卡韦治疗乙型肝炎肝纤维化临床观察[J].中西医结合肝病杂志,2020,30(2):100-102.
[27] 段桂姣,郝蔷薇,吕艳杭,等.柔肝化纤颗粒联合恩替卡韦治疗180例慢性乙型肝炎肝纤维化患者的临床疗效分析[J].中国中医基础医学杂志,2021,27(12):1920-1924.
[28] 马云峰,杨俊恩.柔肝化浊补肾方治疗老年慢性乙型肝炎肝纤维化疗效及机制[J].中国老年学杂志,2021,41(18):3959-3962.
[29] 宁峰,贺鹏志.乙型肝炎肝硬化患者并发脓毒血症的相关危险因素分析[J].医学理论与实践,2024,37(9):1498-1500.
[30] 彭玉静,郭航,陈俊光.应用超声评分联合STE/STQ定量检测肝脏硬度评估慢性乙型肝炎患者肝纤维化程度价值研究[J].实用肝脏病杂志,2024,27(3):345-348.
[31] 赵丘童,黄涛.双歧杆菌三联活菌胶囊治疗乙型肝炎失代偿期肝硬化疗效及对肠道菌群、肠黏膜屏障的影响[J].现代中西医结合杂志, 2024,33(9):1253-1256,1302.
[32] 盛反修,夏金荣,卢仁. 五灵胶囊联合替诺福韦治疗乙型肝炎肝硬化的临床疗效及作用机制[J].中国当代医药,2024,31(13):19-23.

相似文献/References:

[1]邱 勇.桃红四物汤对CCl4诱导肝纤维化小鼠治疗作用及其机制研究[J].陕西中医,2019,(12):1673.
　QIU Yong..Protective effects of Taohong Siwu decoction on CCl4induced hepatic fibrosis model mice[J].,2019,(2):1673.
[2]周 翔,顾 达,童 聪,等.鳖甲煎丸对CCl4诱导小鼠肝纤维化的治疗作用机制研究[J].陕西中医,2022,(2):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
　ZHOU Xiang,GU Da,TONG Cong,et al.Therapeutic mechanism of Biejiajian pills on mice model of liver fibrosis induced by CCl4[J].,2022,(2):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
[3]梁瀞云,唐 燕,司马玲,等.柴胡疏肝散在肝脏疾病中的应用研究进展[J].陕西中医,2022,(11):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
　LIANG Jingyun,TANG Yan,SIMA ling,et al.Application of Chihu Shugan powder in liver diseases[J].,2022,(2):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
[4]胡哲君,汤穆浛,张 锐,等.基于“肝病实脾”理论探讨逍遥散对肝纤维化大鼠肝星状细胞铁死亡的影响[J].陕西中医,2024,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.003]
　HU Zhejun,TANG Muhan,ZHANG Rui,et al.Effect of Xiaoyao powder on ferroptosis of hepatic stellate cells in rats with liver fibrosis based on the theory of “treating liver by nourishing spleen”[J].,2024,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.003]
[5]牛丽娜,窦 婧,马 燕,等.和血柔肝方通过PI3K/Akt/NF-κB信号通路调控自噬相关蛋白改善大鼠肝纤维化机制研究[J].陕西中医,2024,(2):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]
　NIU Lina,DOU Jing,MA Yan,et al.Mechanism of Hexue Rougan decoction in relieve liver fibrosis in rats by regulating autophagy-related proteins through PI3K/Akt/NF-κB signaling pathway[J].,2024,(2):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金资助项目(82204816); 上海市青年科技英才扬帆计划项目(19YF1445200); 上海市卫生健康委员会中发办青年基金资助项目(2018LQ016); 上海中医药大学科研项目(18LK074)
更新日期/Last Update: 2025-02-08